FCH
BMY.RT

Freestone Capital Holdings’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Freestone Capital Holdings’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$225 – 1344
2020
Q3 		$225 Buy
+100
New +$286 ﹤0.01% 1200

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Freestone Capital Holdings's BMY.RT Position: Q4 2020 in Review

Freestone Capital Holdings sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 100 shares — an estimated $225 sold.

Freestone Capital Holdings first reported a position in BMY.RT in Q3 2020 and held it in 1 quarter. The position peaked at $225 in Q3 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Freestone Capital Holdings reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Freestone Capital Holdings sold 100 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $225.
  • Freestone Capital Holdings first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 1 quarter.
  • Freestone Capital Holdings's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $225 in Q3 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Freestone Capital Holdings's 13F filing for Q4 2020, filed 16 Feb 2021.